CG Oncology Q2 net loss $18.9M; cash $552.9M; positive CORE-001 combo data published in Nature Medicine

CG Oncology, Inc.

2024-Q2 EPS reported -$0.63 revenue$640,000

Net loss of $18.9M ($0.28 EPS) vs $11.6M loss ($3.93 EPS) in Q2 2023; R&D spend $18.5M vs $9.8M YoY.
Cash, equivalents and marketable securities $552.9M as of June 30, 2024; runway expected through 2027.
CORE-001 (cretostimogene + pembrolizumab) achieved 54% complete response at 24 months; 100% progression-free survival at 24 months.
BOND-003 monotherapy showed 75.2% CR at any time (n=105); no Grade 3+ AEs or treatment-related discontinuations.
Expanded Access Program initiated first patient dosed in June; primary BOND-003 results expected by end of 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.